Effectiveness of SARS-CoV-2 Vaccines in Hemodialysis Patients
A special issue of Vaccines (ISSN 2076-393X).
Deadline for manuscript submissions: closed (29 September 2023) | Viewed by 6927
Special Issue Editors
Interests: dialysis
2. College of Liberal Arts and Sciences, Tokyo Medical and Dental University, Tokyo, Japan
Interests: clinical trials; epidemiology; public health; research and development; effectiveness study; efficacy and safety; evidence-based medicine; publication practice
Special Issue Information
Dear Colleagues,
The severity and fatality rates of dialysis patients infected with SARS-CoV-2 have been reported to be higher than in the general population. In a primary series of vaccinations, hemodialysis patients have been reported to have lower levels of neutralizing antibodies compared to the general population. However, responses after a booster dose have been reported to be higher in dialysis patients than in the general population. Although the cause of this altered immune response is unknown, determining the relationship between elevated neutralizing antibody titers and the severity of illness or fatality is important. Recently, attention has been paid not only to liquid immunity but also to cellular immunity, and various studies have been conducted on immune responses in dialysis patients. The purpose of this Special Issue is to feature the immune response of SARS-CoV-2 vaccines in hemodialysis patients through basic research, the antibody titer response and cellular immune response through clinical research, and the effect on severity and lethality in clinical practice.
Dr. Kan Kikuchi
Dr. Koki Yamashita
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Vaccines is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- SARS-CoV-2 infection
- SARS-CoV-2 immunology
- SARS-CoV-2 prevention
- SARS-CoV-2 vaccine
- SARS-CoV-2 antibody therapy
- hemodialysis
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue polices can be found here.